CD33 and acute myeloid leukemia: Furthermore, the localized targeting of CD33+ cells by the BiTE in the BM might prevent the selection of HLA-loss AML clones; moreover, the CD33 antigen is also expressed on myeloid-derived suppressor cells, which are involved in hampering immune-based therapies [28].